Literature DB >> 9230219

Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells.

R L Shattuck-Brandt1, A Richmond.   

Abstract

The expression of the CXC chemokine MGSA is often deregulated during viral infection, chronic inflammation, and melanoma tumor progression. In Hs294T melanoma cells, the increased constitutive expression of MGSA is due to increased gene transcription. Moreover, nuclear extracts from unstimulated Hs294T cells contain 19-fold more immunoreactive NF-kappaB p65 than that observed in normal retinal pigment epithelial (ARPE) cells. This increase in NF-kappaB p65 correlates with increased NF-kappaB DNA binding activity in Hs294T nuclear extracts. After stimulation with interleukin 1, Western and electrophoretic mobility shift assay analysis indicate that in both cell types, additional activated NF-kappaB p65 is translocated to the nucleus. However, the rate of postinduction repression of NF-kappaB DNA binding is delayed in Hs294T melanoma cells compared to ARPE cells. Western analysis of whole-cell lysates from both Hs294T and ARPE cells indicates that protein levels of the inhibitor of NF-kappaB, I-kappaB alpha, are 3-fold lower in Hs294T cells. The decrease in I-kappaB alpha cannot be attributed to alterations in the transcription or translation of I-kappaB alpha. Rather, the posttranslational processing has been altered. In Hs294T cells, the half-life of the I-kappaB alpha protein is 45 min, compared to 120 min in ARPE cells. These results indicate that in Hs294T melanoma cells the equilibrium between I-kappaB alpha degradation and resynthesis has been altered, leading to constitutive nuclear translocation and activation of NF-kappaB. Similar mechanisms could also operate in other tumorigenic processes, as well as in viral and chronic inflammatory disorders, to produce high constitutive and unregulated chemokine expression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230219

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury.

Authors:  John A Belperio; Michael P Keane; Marie D Burdick; Vedang Londhe; Ying Ying Xue; Kewang Li; Roderick J Phillips; Robert M Strieter
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents.

Authors:  Henrike Westekemper; Michael Freistuehler; Norbert Bornfeld; Klaus-Peter Steuhl; Max Scheulen; Ralf A Hilger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-07-11       Impact factor: 3.117

3.  Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.

Authors:  Sulochana S Bhandarkar; Jacqueline Bromberg; Carol Carrillo; Ponniah Selvakumar; Rajendra K Sharma; Betsy N Perry; Baskaran Govindarajan; Levi Fried; Allie Sohn; Kalpana Reddy; Jack L Arbiser
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

4.  Transmembrane TNF-alpha mediates "forward" and "reverse" signaling, inducing cell death or survival via the NF-kappaB pathway in Raji Burkitt lymphoma cells.

Authors:  Hailong Zhang; Dan Yan; Xu Shi; Huifang Liang; Yan Pang; Nalin Qin; Hui Chen; Jing Wang; Bingjiao Yin; Xiaodan Jiang; Wei Feng; Wenjie Zhang; Muxiang Zhou; Zhuoya Li
Journal:  J Leukoc Biol       Date:  2008-06-11       Impact factor: 4.962

5.  NF-kappaB controls growth of glioblastomas/astrocytomas.

Authors:  Denise Smith; Takeshi Shimamura; Stephanie Barbera; Bruce E Bejcek
Journal:  Mol Cell Biochem       Date:  2007-09-09       Impact factor: 3.396

Review 6.  Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development.

Authors:  Yarí E Marín; Suzie Chen
Journal:  J Mol Med (Berl)       Date:  2004-08-21       Impact factor: 4.599

Review 7.  Nf-kappa B, chemokine gene transcription and tumour growth.

Authors:  Ann Richmond
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

8.  Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.

Authors:  Ryan Morrison; Stephen M Schleicher; Yunguang Sun; Kenneth J Niermann; Sungjune Kim; Daniel E Spratt; Christine H Chung; Bo Lu
Journal:  J Oncol       Date:  2010-10-12       Impact factor: 4.375

9.  A new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NFkappaB activity.

Authors:  Daniela Sorriento; Alfonso Campanile; Gaetano Santulli; Eleonora Leggiero; Lucio Pastore; Bruno Trimarco; Guido Iaccarino
Journal:  Mol Cancer       Date:  2009-11-09       Impact factor: 27.401

10.  Overexpression of tissue inhibitors of metalloproteinase 2 up-regulates NF-kappaB activity in melanoma cells.

Authors:  Jun Sun; William G Stetler-Stevenson
Journal:  J Mol Signal       Date:  2009-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.